JNJ

What is JNJ?

Founded in 1886 by the Johnson brothers, Johnson & Johnson originally revolutionized the medical world with sterile surgical dressings. Since then, it has transformed into a diversified healthcare titan. After spinning off its consumer health business in 2023, JNJ now operates with a laser focus on two high-growth segments: Innovative Medicine and MedTech. This shift allows the company to focus resources on complex science and high-margin innovation rather than retail goods.

The Innovative Medicine arm is a clinical powerhouse, driven by blockbuster treatments in immunology, oncology, and neuroscience. Products like Stelara and Darzalex have become cornerstones of their revenue, while their emerging pipeline of CAR-T cell therapies represents the next frontier of cancer care. In the MedTech space, JNJ is a world leader in orthopedics, vision, and surgery. Recent acquisitions like Abiomed and the ongoing development of the Ottava robotic system show their deep commitment to heart recovery and digitally-enabled surgery.

Historically, JNJ has navigated massive shifts, from inventing the first-aid kit to becoming a global leader in biotechnology through aggressive acquisitions like Actelion. Financially, they are one of the most stable companies on the planet, holding a rare AAA credit rating and a sixty-year streak of annual dividend increases. While they face significant legal hurdles regarding legacy talc products, their operating margins and free cash flow remain incredibly healthy.

Looking toward 2026, JNJ is positioning itself for a new era of growth. Management is targeting nearly $60 billion in pharmaceutical sales by 2025, with 2026 serving as the pivotal year to offset losses from the Stelara patent cliff through a massive wave of new product launches. You should expect them to remain very aggressive in the M&A market, likely snapping up mid-sized biotech firms to bolster their late-stage pipeline. For a long-term play, JNJ offers a unique mix of defensive stability and exposure to the most advanced medical technology currently under development.

What is the XTRM Indicator?

The XTRM (Extreme) Indicator is a proprietary momentum indicator that measures cumulative time spent in extreme territory. Unlike traditional oscillators like RSI that measure a snapshot in time, XTRM accumulates how long an asset remains in oversold or overbought conditions, providing a deeper understanding of momentum exhaustion.

For JNJ, monitoring the XTRM indicator provides valuable insights into prolonged extreme conditions. When the XTRM drops significantly below zero (especially below -125), Johnson & Johnson has been in oversold territory for an extended period, suggesting potential for a reversal. Conversely, high positive XTRM values indicate extended overbought conditions.

Understanding JNJ XTRM Signals

• Deep Oversold (XTRM below -125): When JNJ XTRM falls below -125, it indicates prolonged time in extreme oversold conditions. This cumulative measure often provides stronger reversal signals than single-day oversold readings.
• Neutral Zone (XTRM near 0): When XTRM hovers around zero, JNJ is in a balanced state without extended extreme conditions. This can indicate consolidation or indecision in the market.
• Overbought (XTRM above +10): An XTRM above +10 indicates JNJ has been in overbought territory for an extended period, potentially signaling an overextended rally and increased risk of pullback.

Daily vs Weekly XTRM for JNJ

This page displays both daily and weekly XTRM for JNJ. The daily XTRM tracks short-term cumulative extremes, useful for identifying swing trading opportunities. The weekly XTRM provides a longer-term perspective on momentum exhaustion, helping investors spot major turning points.

By analyzing both timeframes together, you can identify when Johnson & Johnson is experiencing extreme conditions at multiple time scales, which often leads to the strongest reversal setups.

Historical XTRM Extreme Analysis

Above, we track historical instances when JNJ XTRM dropped below -125 (extreme oversold territory). These periods represent times when Johnson & Johnson spent extended periods in oversold conditions, which historically have presented some of the best buying opportunities. Analyzing how JNJ behaved after reaching these extreme XTRM levels can help inform future trading decisions.